Good day. It's October 4.

Gut health keeps proving itself central to how we age. This week, UCLA researchers found that specific gut bacteria can reveal - and actively drive - how fast your brain is aging. The older your brain looks biologically, the worse the memory, focus, and mood. And the gut microbiome may be at the controls.

The rundown:

Let's get to it. 👇

The essential amino acid leucine boosts cellular energy production by protecting key proteins on mitochondria from being destroyed - a new discovery reveals a specific nutrition-to-metabolism connection that could lead to interventions for energy decline in aging. Leucine is found in eggs, meat, fish, and dairy. ScienceDaily

Oura is building out a health AI stack through its latest acquisition spree - the smart ring company is buying its way into AI-powered health intelligence, positioning Oura as a platform rather than a wearable. The move signals that continuous health monitoring is shifting from data collection to AI interpretation. Longevity.Technology

Strength training may be one of the most powerful tools for staying physically independent as you age - a new analysis reinforces that muscle mass and strength are among the strongest predictors of functional independence into older age, ahead of many pharmaceutical interventions. Two sessions a week is sufficient to see meaningful benefit. ScienceDaily

Faster epigenetic aging is linked to more frequent self-reported memory lapses in daily life - a new study using DunedinPACE, one of the most validated epigenetic aging clocks, found that adults with accelerated biological aging reported more day-to-day memory failures. The link between your biological clock and how sharp you feel on any given Tuesday is apparently measurable. Fight Aging!

Coultreon raised $125 million in a funding round focused on immune resilience - the company targets age-related immune dysfunction, a root cause of multiple chronic diseases and a key driver of biological aging. As the longevity field matures, immune system decline is becoming one of the most serious capital attractors. Longevity.Technology

A new study from UCLA, published October 4, links specific gut bacteria and their chemical byproducts to the speed of brain aging - with older-looking brains also associated with poorer memory, focus, and mood.

The gut-brain axis has been studied for years. What this research adds is a specific, measurable connection between the composition of your gut microbiome - the community of trillions of bacteria living in your digestive system - and how your brain ages biologically. Not just how it functions today. How fast it's getting older.

The mechanism runs through metabolites: chemical compounds that gut bacteria produce as they digest food. These metabolites enter the bloodstream, cross the blood-brain barrier, and directly influence the biochemical environment of the brain. Some promote inflammation. Some support cellular maintenance. Some affect the production of neurotransmitters. What bacteria you carry determines which metabolites your brain is being bathed in, around the clock, for decades.

The science breakdown:

The practical angle: gut microbiome composition can be influenced. It shifts with diet within days - fiber, fermented foods (kefir, kimchi, yogurt), and reduced ultra-processed food all change the bacterial landscape in measurable ways. Unlike genetics, which you can't change, your microbiome is a modifiable system. If specific bacteria are accelerating brain aging, the intervention targets are accessible and dietary.

This also connects to what we covered three weeks ago with Maria Branyas - the world's oldest verified person had a gut microbiome dominated by bifidobacteria, associated with protective effects. The Oct. 4 UCLA study approaches the same gut-brain-aging connection from a different direction: not what protective bacteria might do, but what harmful ones already are.

👉 ScienceDaily

This week's FROM THE CLINIC showed that gut bacteria and their metabolites are linked to brain aging speed. The only way to know whether your gut health is translating into the right metabolic markers - and catch problems early - is to test.

Superpower gives you access to 100+ biomarkers in a single comprehensive blood panel. Done at 2,000+ US labs or with a home visit. Full results with context, tracked over time. $199/year - roughly what most concierge longevity clinics charge per hour.

HSA and FSA eligible. Use code STAYIN20OFF to get $20 off your first purchase.

👉 Check your biomarkers at Superpower

This section contains an affiliate link. We earn a commission if you purchase through it, at no extra cost to you.

ARDD 2026 - the Aging Research and Drug Discovery conference - is taking place this week in Copenhagen. It's the world's largest annual gathering dedicated specifically to aging science and longevity drug development. And this year's main-stage signal is significant.

Eli Lilly and Novo Nordisk both presented longevity data on their GLP-1 drugs. This is new.

Until now, GLP-1 drugs have been framed commercially in disease terms - diabetes, obesity, cardiovascular risk. What Lilly and Novo presented this week at ARDD were aging endpoints: data explicitly examining whether GLP-1 receptor agonism affects biological aging, not just metabolic disease markers.

Novo is exploring consumer indications based on what LT calls the "halo effect" - the growing evidence that GLP-1s have anti-inflammatory and systemic effects across immune-mediated disease, pain, addiction, and more. Lilly is mapping the same territory from a different angle.

The business reading: when the two largest pharmaceutical companies in this drug class show up at an aging conference to present longevity data, the category has officially been claimed by Big Pharma. Startups have been making the GLP-1 aging argument for two years. Now Lilly and Novo are making it themselves, from the main stage, with their own data. That's not a scientific event. That's a market signal.

👉 Longevity.Technology

APOE4 is the most significant genetic risk factor for late-onset Alzheimer's disease. Roughly 25% of the population carries at least one copy. One copy triples the risk of Alzheimer's. Two copies increases it by 8-12x.

For decades, it has been treated largely as fate. New research published October 1 complicates that story.

Scientists found that APOE4 appears to actively damage brain blood vessels and sabotage the cellular systems responsible for clearing harmful proteins - including amyloid and tau, the two proteins most closely associated with Alzheimer's pathology. This was known. What's new is that in experiments, researchers were able to reverse some of these effects.

The damage APOE4 causes to blood vessel integrity and protein clearance is not permanent. It appears to be driven by specific molecular mechanisms that can be targeted. The experiments don't produce a treatment - not yet - but they identify what to target. In drug development, knowing the mechanism is the necessary step before designing the intervention.

The practical note for APOE4 carriers: managing the risk factors that affect brain blood vessels - blood pressure, cardiovascular health, blood sugar, sleep quality - now has a more specific rationale. The same vascular pathways APOE4 damages are the ones that lifestyle factors protect. And biological age testing that tracks inflammatory markers and vascular function gives APOE4 carriers an early read on whether those pathways are staying healthy.

👉 ScienceDaily

This week's FROM THE CLINIC linked specific gut bacteria to brain aging speed. Gundry - a cardiovascular surgeon who retooled his entire practice around the gut-longevity connection - makes the case that your microbiome is the master regulator of how fast you age. Some of his specific dietary claims are contested by mainstream nutritionists; the core thesis about gut health and systemic inflammation is increasingly vindicated by the research. Read it critically. You'll come away with a different relationship with your gut.

👉 Get The Longevity Paradox

Life is a trip 👇